PT2720989T - 1-piperazino-3-fenil-indanos deuterados para o tratamento da esquizofrenia - Google Patents
1-piperazino-3-fenil-indanos deuterados para o tratamento da esquizofreniaInfo
- Publication number
- PT2720989T PT2720989T PT127480465T PT12748046T PT2720989T PT 2720989 T PT2720989 T PT 2720989T PT 127480465 T PT127480465 T PT 127480465T PT 12748046 T PT12748046 T PT 12748046T PT 2720989 T PT2720989 T PT 2720989T
- Authority
- PT
- Portugal
- Prior art keywords
- piperazino
- deuterated
- schizophrenia
- treatment
- indanes
- Prior art date
Links
- QPABODDHXQJCDN-UHFFFAOYSA-N 1-(3-phenyl-2,3-dihydro-1h-inden-1-yl)piperazine Chemical class C12=CC=CC=C2C(C=2C=CC=CC=2)CC1N1CCNCC1 QPABODDHXQJCDN-UHFFFAOYSA-N 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161498651P | 2011-06-20 | 2011-06-20 | |
US201161537103P | 2011-09-21 | 2011-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2720989T true PT2720989T (pt) | 2016-11-07 |
Family
ID=46682855
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT16179882T PT3135656T (pt) | 2011-06-20 | 2012-06-19 | 1-piperazino-3-fenil-indanos deuterados para o tratamento da esquizofrenia |
PT127480465T PT2720989T (pt) | 2011-06-20 | 2012-06-19 | 1-piperazino-3-fenil-indanos deuterados para o tratamento da esquizofrenia |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT16179882T PT3135656T (pt) | 2011-06-20 | 2012-06-19 | 1-piperazino-3-fenil-indanos deuterados para o tratamento da esquizofrenia |
Country Status (40)
Country | Link |
---|---|
US (8) | US8575174B2 (pt) |
EP (4) | EP3135656B1 (pt) |
JP (1) | JP5668177B2 (pt) |
KR (2) | KR101879474B1 (pt) |
CN (1) | CN103649019B (pt) |
AP (1) | AP3310A (pt) |
AR (1) | AR086987A1 (pt) |
AU (1) | AU2012273657B2 (pt) |
BR (1) | BR112013031702B1 (pt) |
CA (1) | CA2837820C (pt) |
CL (1) | CL2013003646A1 (pt) |
CO (1) | CO6821965A2 (pt) |
CR (1) | CR20130654A (pt) |
CY (2) | CY1118158T1 (pt) |
DK (2) | DK2720989T3 (pt) |
DO (1) | DOP2013000305A (pt) |
EA (1) | EA024651B1 (pt) |
EC (1) | ECSP14013155A (pt) |
ES (3) | ES2939477T3 (pt) |
GE (1) | GEP201706655B (pt) |
GT (1) | GT201300304A (pt) |
HK (1) | HK1197228A1 (pt) |
HR (2) | HRP20161348T1 (pt) |
HU (2) | HUE030883T2 (pt) |
IL (1) | IL229640B (pt) |
JO (1) | JO3128B1 (pt) |
LT (2) | LT2720989T (pt) |
MA (1) | MA35268B1 (pt) |
MD (1) | MD4538C1 (pt) |
ME (2) | ME02513B (pt) |
MX (1) | MX339552B (pt) |
MY (1) | MY196998A (pt) |
PE (2) | PE20150928A1 (pt) |
PL (2) | PL2720989T3 (pt) |
PT (2) | PT3135656T (pt) |
RS (2) | RS58546B1 (pt) |
SI (2) | SI2720989T1 (pt) |
SM (1) | SMT201600383B (pt) |
TW (3) | TWI659741B (pt) |
WO (1) | WO2012176066A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101879474B1 (ko) * | 2011-06-20 | 2018-07-17 | 하. 룬드벡 아크티에셀스카브 | 정신 분열증의 치료를 위한 중수소화 1-피페라지노-3-페닐 인단 |
AR094054A1 (es) * | 2012-12-19 | 2015-07-08 | H Lundbeck As | 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma |
ES2909388T3 (es) | 2017-09-07 | 2022-05-06 | Otsuka Pharma Co Ltd | Procedimiento industrial de monoalquilación de un nitrógeno de piperidina en derivados de piperidina con alquilo deuterado |
EP3873885A1 (en) | 2018-10-29 | 2021-09-08 | H. Lundbeck A/S | Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts |
CN113056457A (zh) | 2018-12-03 | 2021-06-29 | H.隆德贝克有限公司 | 4-((1R,3S)-6-氯-3-苯基-2,3-二氢-1H-茚-1-基)-1,2,2-三甲基哌嗪和4-((1R,3S)-6-氯-3-(苯基-d5)-2,3-二氢-1H-茚-1-基)-2,2-二甲基-1-(甲基-d3)哌嗪的前药 |
EP3897507A4 (en) * | 2018-12-21 | 2022-09-14 | Terran Biosciences, Inc. | DEUTERED FORMS AND DERIVATIVES OF VOLINANSERIN |
KR20210139317A (ko) | 2019-03-13 | 2021-11-22 | 오츠카 세이야쿠 가부시키가이샤 | 2급 아민을 함유하는 화합물의 아민 부분에 중수소 저급 알킬을 도입하는 방법 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ196284A (en) | 1980-02-29 | 1983-12-16 | Kefalas As | 1-piperazino-3-phenylindane derivatives:pharmaceutical compositions |
GB8427125D0 (en) | 1984-10-26 | 1984-12-05 | Lundbeck & Co As H | Organic compounds |
DK286990D0 (da) | 1990-12-04 | 1990-12-04 | Lundbeck & Co As H | Indanderivater |
DK55192D0 (da) * | 1992-04-28 | 1992-04-28 | Lundbeck & Co As H | 1-piperazino-1,2-dihydroindenderivater |
US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
AU707748B2 (en) | 1994-03-25 | 1999-07-22 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
CN101935305B (zh) * | 2003-08-18 | 2013-04-10 | H.隆德贝克有限公司 | 反式-4-((1r,3s)-6-氯-3-苯基茚满-1-基)-1,2,2-三甲基哌嗪及其盐的制备方法及所用中间体 |
MXPA06001938A (es) | 2003-08-18 | 2006-05-17 | Lundbeck & Co As H | Trans-1-(6-cloro-3-fenilindan-1-il)-3,3-dimetilpiperazina. |
TWI376373B (en) | 2005-02-16 | 2012-11-11 | Lundbeck & Co As H | Crystalline base of a pharmaceutical compound |
TWI453198B (zh) | 2005-02-16 | 2014-09-21 | Lundbeck & Co As H | 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s)-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法 |
WO2006086985A1 (en) | 2005-02-16 | 2006-08-24 | H. Lundbeck A/S | Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
US7863274B2 (en) | 2005-07-29 | 2011-01-04 | Concert Pharmaceuticals Inc. | Deuterium enriched analogues of tadalafil as PDE5 inhibitors |
CN101273024A (zh) | 2005-07-29 | 2008-09-24 | 康瑟特制药公司 | 新颖苯并[d][1,3]-二氧杂环戊烯衍生物 |
AU2006320655A1 (en) | 2005-12-01 | 2007-06-07 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
JP4986462B2 (ja) | 2006-01-27 | 2012-07-25 | シャープ株式会社 | 太陽電池ストリングおよびその製造方法、ならびに、その太陽電池ストリングを用いる太陽電池モジュール |
TW200819426A (en) | 2006-08-31 | 2008-05-01 | Lundbeck & Co As H | Novel indane compounds |
WO2008128166A1 (en) | 2007-04-13 | 2008-10-23 | Concert Pharmaceuticals Inc. | Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds |
CA2686545C (en) | 2007-04-19 | 2010-11-02 | Concert Pharmaceuticals Inc. | Deuterated morpholinyl compounds |
CN101711237B (zh) | 2007-06-12 | 2013-08-07 | 康塞特制药公司 | 氮杂肽衍生物 |
US20090062303A1 (en) | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched ziprasidone |
NZ589571A (en) | 2008-05-07 | 2012-07-27 | Lundbeck & Co As H | Method for treating cognitive deficits using trans-4-((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine |
BRPI0919165A2 (pt) | 2008-10-03 | 2015-12-08 | Lundbeck & Co As H | composição farmacêutica,e, uso de um composto |
EP2362865A2 (en) | 2008-10-28 | 2011-09-07 | Concert Pharmaceuticals Inc. | Deuterated 2-propylpentanoic acid compounds |
US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
US8658236B2 (en) * | 2009-08-21 | 2014-02-25 | Deuteria Beverages, Llc | Alcoholic compositions having a lowered risk of acetaldehydemia |
CN102020522A (zh) * | 2009-09-21 | 2011-04-20 | 陈松源 | 氘代药物的制备方法和应用 |
US8278460B2 (en) | 2009-10-15 | 2012-10-02 | Concert Pharmaceuticals, Inc. | Substituted benzimidazoles |
WO2011059080A1 (ja) * | 2009-11-16 | 2011-05-19 | 第一三共株式会社 | 同位体置換されたジアミン誘導体 |
KR101879474B1 (ko) * | 2011-06-20 | 2018-07-17 | 하. 룬드벡 아크티에셀스카브 | 정신 분열증의 치료를 위한 중수소화 1-피페라지노-3-페닐 인단 |
-
2012
- 2012-06-19 KR KR1020137033717A patent/KR101879474B1/ko active IP Right Grant
- 2012-06-19 EP EP16179882.2A patent/EP3135656B1/en active Active
- 2012-06-19 LT LTEP12748046.5T patent/LT2720989T/lt unknown
- 2012-06-19 HU HUE12748046A patent/HUE030883T2/en unknown
- 2012-06-19 MY MYPI2021002383A patent/MY196998A/en unknown
- 2012-06-19 CA CA2837820A patent/CA2837820C/en active Active
- 2012-06-19 WO PCT/IB2012/001386 patent/WO2012176066A1/en active Application Filing
- 2012-06-19 KR KR1020187018343A patent/KR101939546B1/ko active IP Right Grant
- 2012-06-19 HU HUE16179882A patent/HUE044043T2/hu unknown
- 2012-06-19 MX MX2013014849A patent/MX339552B/es active IP Right Grant
- 2012-06-19 ES ES19151618T patent/ES2939477T3/es active Active
- 2012-06-19 PE PE2015000596A patent/PE20150928A1/es active IP Right Grant
- 2012-06-19 PE PE2013002857A patent/PE20141113A1/es not_active Application Discontinuation
- 2012-06-19 RS RS20190429A patent/RS58546B1/sr unknown
- 2012-06-19 PT PT16179882T patent/PT3135656T/pt unknown
- 2012-06-19 LT LTEP16179882.2T patent/LT3135656T/lt unknown
- 2012-06-19 CN CN201280029731.8A patent/CN103649019B/zh active Active
- 2012-06-19 MD MDA20140004A patent/MD4538C1/ro active IP Right Grant
- 2012-06-19 EP EP23150855.7A patent/EP4215512A1/en active Pending
- 2012-06-19 JO JOP/2012/0161A patent/JO3128B1/ar active
- 2012-06-19 ME MEP-2016-226A patent/ME02513B/me unknown
- 2012-06-19 DK DK12748046.5T patent/DK2720989T3/en active
- 2012-06-19 RS RS20160916A patent/RS55304B1/sr unknown
- 2012-06-19 PT PT127480465T patent/PT2720989T/pt unknown
- 2012-06-19 DK DK16179882.2T patent/DK3135656T3/en active
- 2012-06-19 EP EP19151618.6A patent/EP3508468B1/en active Active
- 2012-06-19 BR BR112013031702-7A patent/BR112013031702B1/pt active IP Right Grant
- 2012-06-19 EA EA201490045A patent/EA024651B1/ru not_active IP Right Cessation
- 2012-06-19 ME MEP-2019-93A patent/ME03375B/me unknown
- 2012-06-19 EP EP12748046.5A patent/EP2720989B1/en active Active
- 2012-06-19 AP AP2013007338A patent/AP3310A/xx active
- 2012-06-19 PL PL12748046T patent/PL2720989T3/pl unknown
- 2012-06-19 PL PL16179882T patent/PL3135656T3/pl unknown
- 2012-06-19 GE GEAP201213350A patent/GEP201706655B/en unknown
- 2012-06-19 ES ES12748046.5T patent/ES2601213T3/es active Active
- 2012-06-19 US US13/527,364 patent/US8575174B2/en active Active
- 2012-06-19 ES ES16179882T patent/ES2719145T3/es active Active
- 2012-06-19 AR ARP120102179 patent/AR086987A1/es active IP Right Grant
- 2012-06-19 AU AU2012273657A patent/AU2012273657B2/en active Active
- 2012-06-19 JP JP2014516459A patent/JP5668177B2/ja active Active
- 2012-06-19 SI SI201230744A patent/SI2720989T1/sl unknown
- 2012-06-19 SI SI201231582T patent/SI3135656T1/sl unknown
- 2012-06-20 TW TW107113541A patent/TWI659741B/zh active
- 2012-06-20 TW TW101122028A patent/TWI627956B/zh active
- 2012-06-20 TW TW106107563A patent/TWI614234B/zh active
-
2013
- 2013-06-24 US US13/924,849 patent/US9012453B2/en active Active
- 2013-11-26 IL IL229640A patent/IL229640B/en active IP Right Grant
- 2013-12-09 GT GT201300304A patent/GT201300304A/es unknown
- 2013-12-13 CR CR20130654A patent/CR20130654A/es unknown
- 2013-12-16 DO DO2013000305A patent/DOP2013000305A/es unknown
- 2013-12-19 CO CO13296680A patent/CO6821965A2/es active IP Right Grant
- 2013-12-19 CL CL2013003646A patent/CL2013003646A1/es unknown
-
2014
- 2014-01-16 MA MA36688A patent/MA35268B1/fr unknown
- 2014-01-17 EC ECSP14013155 patent/ECSP14013155A/es unknown
- 2014-10-22 HK HK14110519A patent/HK1197228A1/zh unknown
-
2015
- 2015-03-13 US US14/656,925 patent/US9216961B2/en active Active
- 2015-11-16 US US14/941,800 patent/US9617231B2/en active Active
-
2016
- 2016-10-17 HR HRP20161348TT patent/HRP20161348T1/hr unknown
- 2016-10-26 CY CY20161101089T patent/CY1118158T1/el unknown
- 2016-10-26 SM SM201600383T patent/SMT201600383B/it unknown
-
2017
- 2017-02-17 US US15/435,826 patent/US10118907B2/en active Active
-
2018
- 2018-09-28 US US16/146,625 patent/US10501427B2/en active Active
-
2019
- 2019-03-27 HR HRP20190593TT patent/HRP20190593T1/hr unknown
- 2019-04-02 CY CY20191100368T patent/CY1121514T1/el unknown
- 2019-11-04 US US16/672,870 patent/US11059798B2/en active Active
-
2021
- 2021-06-07 US US17/340,201 patent/US20220119362A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1244183A1 (zh) | Ivacaftor的氘化衍生物 | |
EP2723384A4 (en) | TREATMENT OF PROTEINOPATHIES | |
HRP20190593T1 (hr) | Deuterirani 1-piperazino-3-fenil indani za liječenje shizofrenije | |
HUE047354T2 (hu) | Ivacaftor deuterizált származékai | |
EP2773754A4 (en) | Methods of Treatment | |
EP2717855A4 (en) | PROCESSING METHODS | |
GB201110095D0 (en) | Method of treatment | |
GB201106960D0 (en) | Treatment of waste | |
HK1199261A1 (en) | Methods for treatment of diseases | |
EP2709665A4 (en) | TREATMENT OF PSORIASIS | |
ZA201309613B (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
EP2791324A4 (en) | PROCESSING METHOD | |
HK1199818A1 (en) | Treatment of seborrhoea | |
GB201118065D0 (en) | Treatment of movement disorders | |
GB201110602D0 (en) | Methods of treatment | |
GB201109737D0 (en) | Methods of treatment | |
EP2696872A4 (en) | TREATMENT OF GLAUCOMA | |
GB201121044D0 (en) | Treatment of solutions | |
GB201118269D0 (en) | Treatment of cardiovascular disease | |
GB201111530D0 (en) | Method of treatment | |
GB201109509D0 (en) | Method of treatment | |
GB201109266D0 (en) | Method of treatment | |
GB201107988D0 (en) | Treatment of cardiovascular disease | |
GB201103044D0 (en) | Method of treatment |